Japan Writing in the June edition of DIA’s Global Forum magazine, representatives of Japanese pharmaceutical companies with US operations outline how the COVID-19 pandemic affected their ongoing clinical studies. The spread of COVID-19 and the resulting social activity restrictions have severely impacted drug development and threatened the continuity of clinical…
Saudi Arabia Georg Schroeckenfuchs, Novartis’ president MEA and head of its Gulf and Saudi Country Group, explains how the company’s objectives are aligned with Saudi Arabia’s Vision 2030, the progress made towards the nationalization of its Saudi workforce, the potential impact of changes in the tender process, and why Novartis is uniquely…
Australia Regular PharmaBoardroom contributor Brendan Shaw outlines how his home country of Australia has so far successfully managed to avoid the worst of the COVID-19 pandemic, providing opportunities for the life sciences industry to invest in new facilities, research and development in a post-pandemic world. Australia, the island continent A…
Saudi Arabia Haitham Habashi, general manager for Merck Saudi Arabia, outlines his affiliate’s approach to the big reforms shaping the country’s healthcare system, discusses the new public procurement process, and explains why Vision 2030 means transformative opportunities for Saudis, women, and health. Moreover, he highlights Merck’s manufacturing in Saudi Arabia and its…
Australia In an exclusive new podcast, DIA Global Forum Australia/New Zealand Regional Editor Richard Day (University of New South Wales, Medicine, St. Vincent’s Hospital) and John Skeritt, Head of Australia’s Therapeutic Goods Administration (TGA), discuss regulatory strategies and other initiatives designed to help nurture clinical research and product development in Australia post-pandemic. With…
Switzerland Susanne Caspar, CEO at Swiss natural API producer Linnea, talks about her first few months in the company, the pharmaceutical industry’s growing embrace of natural ingredients, and why Linnea has made the move into cannabis API production. 2020 was defined by an increase in demand for dietary supplements because…
Switzerland Georg Boonen, CEO of Switzerland’s leading phytopharmaceutical player Max Zeller, discusses the company’s expanded market position at home and abroad, how COVID-19 and a reconsideration of preventive healthcare could be an inflection point for phytopharma, and what keeps him motivated after 22 years at the firm. COVID has led…
Japan Following on from our recent compilations of 2020 new drug approvals in the USA, China, and Switzerland, see below for the Japanese PMDA’s new drug approvals list for April-October 2020. Made with Visme Infographic Maker
Switzerland Switzerland is a crucial country for MSD’s global network, employing over 1000 people in local, regional, and global functions across four sites in Lucerne and a newly opened site in Zurich specialising in R&D, data management, and commercialisation. With 25 ongoing clinical trials per year, Switzerland is an important country…
Switzerland Clinerion, a leader in real-world data solutions, is helping bring medical data informatics to the life sciences industry. CEO Barış Erdoğan explains how the company is creating and applying technology to significantly reduce the drug development timeline. Clinerion uses Big Data analytics technologies to help hospitals, pharmaceutical companies and research…
Norway Filip Standaert outlines the significance of the Nordic cluster to J&J’s medical device operations in Europe, how the affiliate responded to the COVID-19 crisis, and the ways in which J&J is aiming to contribute to driving efficiencies within the Norwegian healthcare system. There is still change management to be…
Norway Christian Probst gives an overview of GSK Norway’s broad portfolio, market access hurdles, and the importance of bringing clinical trials back to Norway. Probst also touches on how the country’s impressive digital footprint can be better leveraged and GSK’s role in Norway as one of the world’s leading vaccine companies.…
See our Cookie Privacy Policy Here